AstraZeneca PLC (AZN)vsHinge Health, Inc. (HNGE)
AZN
AstraZeneca PLC
$160.17
+0.33%
HEALTHCARE · Cap: $252.33B
HNGE
Hinge Health, Inc.
$88.59
+0.37%
HEALTHCARE · Cap: $7.37B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 8422% more annual revenue ($61.37B vs $720.06M). AZN leads profitability with a 17.0% profit margin vs 15.1%. HNGE trades at a lower P/E of 11.3x. AZN earns a higher WallStSmart Score of 60/100 (C+).
AZN
Buy60
out of 100
Grade: C+
HNGE
Buy52
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+18.4%
Fair Value
$196.10
Current Price
$160.17
$35.93 discount
Intrinsic value data unavailable for HNGE.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Attractively priced relative to earnings
Revenue surging 53.0% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
2.5% earnings growth
Distress zone — elevated risk
Weak financial health signals
Trading at 20.7x book value
ROE of -197.2% — below average capital efficiency
Earnings declined 68.4%
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.28 suggests the stock is reasonably priced for its growth.
Bull Case : HNGE
The strongest argument for HNGE centers on P/E Ratio, Revenue Growth, Debt/Equity. Profitability is solid with margins at 15.1% and operating margin at 19.0%. Revenue growth of 53.0% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are EPS Growth, Altman Z-Score.
Bear Case : HNGE
The primary concerns for HNGE are Piotroski F-Score, Price/Book, Return on Equity.
Key Dynamics to Monitor
AZN profiles as a mature stock while HNGE is a growth play — different risk/reward profiles.
HNGE is growing revenue faster at 53.0% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
AZN scores higher overall (60/100 vs 52/100), backed by strong 17.0% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Hinge Health, Inc.
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
Hinge Health, Inc. develops health care software for joint and muscle health. The company is headquartered in San Francisco, California.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?